

REVIEW

Mendelian randomization and pleiotropy analysis

Xiaofeng Zhu*

Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA

* Correspondence: xxz10@case.edu

Received April 1, 2020; Revised May 16, 2020; Accepted May 21, 2020

Background: Mendelian randomization (MR) analysis has become popular in inferring and estimating the causality of an exposure on an outcome due to the success of genome wide association studies. Many statistical approaches have been developed and each of these methods require specific assumptions.

Results: In this article, we review the pros and cons of these methods. We use an example of high-density lipoprotein cholesterol on coronary artery disease to illuminate the challenges in Mendelian randomization investigation.

Conclusion: The current available MR approaches allow us to study causality among risk factors and outcomes. However, novel approaches are desirable for overcoming multiple source confounding of risk factors and an outcome in MR analysis.

Keywords: Mendelian randomization; causality; summary statistics; confounding; instrumental variable

Author summary: Mendelian randomization analysis is a popular approach to studying the causality of exposures on an outcome, and it shares similarities with randomized controlled trials. Since MR is based on observational data, it requires assumptions that are difficult to validate. We review the current developed MR approaches and the challenges in performing MR analysis and interpreting the results.

INTRODUCTION

Randomized controlled trials (RCTs) are considered as the gold standard to establish a causal relationship between an exposure and an outcome in epidemiology studies. Many associations observed in epidemiological studies have failed to be replicated in RCTs, such as fiber and colon cancer [1], vitamin E, cardiovascular disease and lung cancer [2,3], and vitamin C and cardiovascular disease [4]. The failed replications in RCTs can be potentially attributed to confounding, reverse causation, and various biases [5,6]. Thus, RCTs are the primary tool to establish a causation between a risk factor and an outcome, but they come with a high cost. To circumvent the high cost in RCTs, Mendelian randomization (MR) has become a widely used epidemiological approach to infer causality of an exposure to a disease outcome [7–9]. This is benefitted from the rapid identifications of genetic variants associated

with complex traits in large genome wide associations (GWAS) [10]. Intuitively, MR shares a similarity with RCTs (Fig. 1). In RCTs, the enrolled patients are randomly assigned to a treatment or a control group to eliminate potential confounding associated with both the treatment and the outcome. Therefore, causal effect can be estimated in an unbiased fashion. In contrast, MR assigns subjects based on their carried alleles, which are inherited from their parents. Since the alleles are transmitted from parents to offspring randomly, individuals are therefore divided into different groups randomly based on their genotypes. If the allele is associated with an exposure and the exposure causally affects the disease, we will observe different disease frequencies among different genotype groups. Otherwise, such an association will not be present if the exposure does not contribute to the disease. Furthermore, this association is independent of environment confounding because the allele predisposes to environment [8]. This




Figure 1. Comparison between RCT and MR designs.

idea was originally proposed by Katan [9] who focused on testing for the association of a genotype and an outcome rather than estimating the effect of an exposure to an outcome. Hence, the data on exposure in Katan's approach is not required given that the association between the genotype and the exposure has been established. Recent development of MR focus on the causal effect estimation by using the genetic markers as "instrumental variables (IVs)" [8,11]. With that many large GWASs having already collected genomic data, the MR approach is an appealing method to estimate the causal effect between an exposure and an outcome with much less cost than RCTs.

Early MR approach is based on having one genetic marker as an IV. To be a valid IV, the genetic marker must satisfy the following three IV conditions [8]: (IV1) the genetic marker is reliably associated with the exposure, (IV2) the genetic marker is associated with the outcome only through the exposure, and (IV3) the genetic marker is independent of unobserved confounders that affect the exposure and outcome after conditioning on observed confounders. The IV2 condition is also referred to as the exclusion restriction, and both IV2 and IV3 are difficult to be fully examined in reality [12]. VanderWeele *et al.* [12] listed multiple exclusion restriction violations in MR analysis when a single genetic marker is used for IV. The potential violations include: pleiotropic genetic instrument variable; measurement error; time-dependent exposure; reverse causation; sample selection bias; linkage disequilibrium between the genetic marker and a causal variant; and population structure. All the above violations will create a pathway from the genetic marker to the outcome that does not go through the exposure, therefore, bringing bias into the causal estimation. An IV with pleiotropic effect is a major concern in a MR analysis. In the past decade, GWASs have been successful in identifying genetic variants associated with complex traits ([https://](https://www.genome.gov/gwastudies/)

www.genome.gov/gwastudies/). A recent study showed that 90% of the identified variants are associated with multiple traits [13], a term that is characterized as cross phenotype association [14]. This also suggests pleiotropic variants are widely spread across traits. Such pleiotropic variants can be detected by analyzing multiple traits together [15], but the method itself does not indicate which variant is a pleiotropic variant. Thus, methods of using multiple genetic variants for IVs in MR analysis have been rapidly developed [16], and because the impact of some of the violations is alleviated when multiple IVs are applied.

In this review, I will discuss MR approaches using multiple genetic variants as IVs with summary statistics. I will also discuss the pros and cons for these methods (Table 1).

STATISTICAL METHODS FOR MR APPROACHES USING SUMMARY STATISTICS

IVW and MR-Egger

When individual level data is available, an MR analysis can be performed by using the standard two-stage least squares (TSLS) [17]. The same idea can be extended to the data where only summary statistics are available. We denote E and Y as the exposure and the outcome described in Fig. 2, respectively. The goal of MR is to establish the causal relationship from the exposure E to the outcome Y using independent genetic variants as the IVs. We assume that the association of an IV and the exposure has already been reliably established in GWAS. Because the genetic variants associated with the exposure are possibly associated with the outcome through different paths (Fig. 2), we use the following general models:

Table 1 Summary of MR methods

Methods	Conditions	Strengths	Weakness	Software Web address
IVW	Valid IVs or Balanced pleiotropy	Most efficient, Computationally fast	Large bias with invalid IVs	1
MR-Egger	InSIDE	Less requirement for IVs, Computationally fast	Less efficient, Sensitive to outliers	1
Weighted median	>50% valid IVs	Robust to outliers, Computationally fast	Sensitive to selecting IVs	1
MBE	ZEMPA*	Robust to outliers, Computationally fast	Less efficient, Depending on bandwidth parameter	1
MR-Robust	Robust to outliers	Efficient with valid IVs	Inflated FPR with invalid IVs	2
MR-Lasso	Robust to outliers	Efficient with valid IVs	Inflated FPR with invalid IVs	2
MRMix	ZEMPA*	Robust to outliers	Inflated FPR for some cases, Computationally slow	3
MR-PRESSO	>50% valid IVs	Detect pleiotropy variants	Inflated FPR with invalid IVs, Requires simulations/Computational intense	4
iMRP	>50% valid IVs	Identify pleiotropy variants, computationally fast	Inflated FPR with invalid IVs	5

* ZEMPA: the zero modal pleiotropy assumption

1. <https://cran.r-project.org/web/packages/MendelianRandomization/index.html>
2. <http://cran.r-project.org/package=robustbase>
3. <https://github.com/gqi/MRMix>
4. <https://github.com/rondolab/MR-PRESSO>
5. Available from the author




Figure 2. A causal path diagram for multiple instrumental variables.

$$E = \sum_{i=1}^{n_1} \gamma_i G_i + \sum_{i=1}^{n_2} \gamma_{1i} G'_i + U + \varepsilon_1, \tag{1}$$

$$Y = \beta E + \sum_{i=1}^{n_2} \gamma_{2i} G'_i + U + \varepsilon_2, \tag{2}$$

where γ_i is the direct contribution of the variant G_i to the exposure E , γ_{1i} and γ_{2i} are the direct contributions of variant G'_i to traits E and Y , β is the causal effect of E to trait Y , U represents confounding factors, and ε_1 and ε_2 are error terms, respectively. We use G_i and G'_i to separately represent two kinds of genetic IVs, that the

contribution of G_i ($i = 1, \dots, n_1$) to the outcome Y is mediated through the exposure E , and G'_i has a pleiotropic effect for the exposure and the outcome in independent paths ($\gamma_{1i} \neq 0$ and $\gamma_{2i} \neq 0$). In literature G_i and G'_i are often referred to as a vertical and a horizontal pleiotropy (Fig. 2). In the case of horizontal pleiotropy, there is a direct path from its genetic variant G to the outcome Y besides through the exposure E , which causes a biased causal effect estimate in an MR analysis.

Let $\hat{\gamma}_i$ and $\hat{\gamma}_{1i}$ be the estimated effect sizes of variants G_i and G'_i on the exposure E from the GWAS, respectively. Correspondingly, let $\hat{\Gamma}_i$ and $\hat{\Gamma}_{1i}$ be the estimated effect sizes of variants G_i and G'_i on the outcome Y , respectively. From the Eqs. (1) and (2), we observe that $E(\hat{\Gamma}_{1i}) = \beta E(\hat{\gamma}_{1i})$ for G_i , and $E(\hat{\Gamma}_{1i}) = \beta E(\hat{\gamma}_{1i}) + \gamma_{2i}$ for the variant G'_i .

In general, we can estimate the causal effect and its variance from the exposure to the outcome without differentiating G_i and G'_i by the following equation [18]

$$\hat{\beta}_i = \frac{\hat{\Gamma}_i}{\hat{\gamma}_i}, \tag{3}$$

$$\text{var}(\hat{\beta}_i) = \frac{\text{var}(\hat{\Gamma}_i)}{\hat{\gamma}_i^2} + \frac{\hat{\Gamma}_i^2}{\hat{\gamma}_i^4} \text{var}(\hat{\gamma}_i) - 2 \frac{\hat{\Gamma}_i^2}{\hat{\gamma}_i^3} \text{cov}(\hat{\Gamma}_i, \hat{\gamma}_i).$$

It is apparent that the causal estimate $\hat{\beta}_i$ is unbiased based on G_i but biased based on G'_i . The bias for G'_i is induced by the nonzero effect γ_{2i} , or horizontal pleiotropy. Because $\hat{\beta}_i$ is inversely proportional to $\hat{\gamma}_i$, smaller effect size of IV leads to a larger bias of the causal effect estimation. The MR analysis based on a single IV has a poor statistical power and potentially a large bias because

$$\hat{\beta}_{IVW} = \frac{\sum_{i=1}^{n_1} \hat{\gamma}_i^2 \hat{\beta}_i / \text{var}(\hat{\Gamma}_i) + \sum_{i=1}^{n_2} \hat{\gamma}_{1i}^2 \hat{\beta}_i / \text{var}(\hat{\Gamma}_i) + \sum_{i=1}^{n_2} \hat{\gamma}_{1i}^2 \hat{\beta}_{1i} / \text{var}(\hat{\Gamma}_{1i})}{\sum_{i=1}^{n_1} \hat{\gamma}_i^2 / \text{var}(\hat{\Gamma}_i) + \sum_{i=1}^{n_2} \hat{\gamma}_{1i}^2 / \text{var}(\hat{\Gamma}_{1i})} \tag{4}$$

This $\hat{\beta}_{IVW}$ is referred to as an inverse-variance weighted (IVW) estimate, which is calculated by assuming all the genetic variants are in linkage equilibrium. The IVW estimate can be calculated from summary statistics, an advantage over TSLS that requires individual-level data.

$$\text{Bias of } \hat{\beta}_{IVW} = \frac{\sum_{i=1}^{n_2} \hat{\gamma}_{1i}^2 \gamma_{2i} / \text{var}(\hat{\Gamma}_{1i})}{\sum_{i=1}^{n_1} \hat{\gamma}_i^2 / \text{var}(\hat{\Gamma}_i) + \sum_{i=1}^{n_2} \hat{\gamma}_{1i}^2 / \text{var}(\hat{\Gamma}_{1i})}$$

which comes from the average effect of the pleiotropic variants. If the pleiotropic effects happen to cancel out, the bias term tends to zero. When the pleiotropic effect γ_{2i} on the outcome is independent of the effect γ_{1i} on the exposure, or $\text{cov}(\gamma_{2i}, \gamma_{1i}) = 0$, the bias can approximate to 0. This condition is referred to as the InSIDE (Instrument Strength Independent of Direct Effect) assumption and can be viewed as a weaker version of the exclusion restriction assumption [22]. Asymptotically, the InSIDE assumption will guarantee the bias tends to zero. In reality, the InSIDE assumption can be difficult to satisfy. To solve this problem, Bowden *et al.* [22] adopted the idea of Egger’s test, which assesses small study bias in meta-analysis in epidemiology studies, into the MR analysis. They named this method as MR-Egger regression [23].

Without specifically distinguishing G_i and G'_i , we consider a linear regression of the $\hat{\Gamma}_i$ coefficients on $\hat{\gamma}_i$ coefficients for a set of IVs,

$$\hat{\Gamma}_i = \beta_0 + \beta \hat{\gamma}_i + \varepsilon_i, \quad i = 1, 2, \dots, n, \tag{5}$$

where $\hat{\Gamma}_i$ and $\hat{\gamma}_i$ represent the regression coefficients of the i^{th} IV for the outcome and the exposure, respectively. The error term ε_i follows a normal distribution: $\varepsilon_i \sim N(0, \text{var}(\hat{\Gamma}_i))$. When regression model (5) constrains the intercept $\beta_0 = 0$, the regression coefficient estimate of β corresponds to the IVW estimate. Alternatively, when regression model (5) includes the intercept term β_0 , the regression coefficient estimate of β corresponds to the MR-Egger estimate. Testing $\beta_0 = 0$ also assesses the presence of pleiotropic variants. The $\hat{\beta}_0$ itself is interpreted

of the small variance explained by the IV. Therefore, using multiple IVs has been popular. Multiple IVs may partially mitigate the bias because it is possible to cancel the bias effect due to the nonzero effects of γ_{2i} [8]. For multiple genetic variants, the causal effect of the exposure on the outcome is estimated by a weighted meta-analysis approach [19–21] given by

as an estimate of the average pleiotropic effects [22]. When the InSIDE assumption is satisfied with balanced pleiotropy, referring to γ_{2i} in Eq. (2) taking positive and negative values randomly, both IVW and MR-Egger approaches have unbiased causal estimate. In the presence of directional pleiotropy, the MR-Egger estimate is still consistent as long as the InSIDE assumption is satisfied, but IVW is not [22]. However, the MR-Egger estimator has a larger standard error than the IVW estimator. Intuitively, this is not surprising because an additional parameter is required for MR-egger, and the pleiotropic IVs will increase the uncertainty in the regression analysis. When sample sizes of GWAS are relatively small, MR-Egger estimator could be even worse [24].

Weighted median and mode-based estimate

An extension of the IVW is the weighted median estimator [25], which is less biased than IVW but more powerful than MR-Egger. The weighted median estimator takes the media of the $\hat{\beta}_i$ of individual genetic variants in Eq. (3), either using equal weights or the inverse of the variance of

the ratio estimates by $\frac{\hat{\gamma}_i^2}{\text{var}(\hat{\Gamma}_i)}$. The weighted median

estimator has a consistent causal estimator when less than 50% instrumental variables are invalid. Because the weighted median estimate is calculated by a single IV (median) when the number of IVs is odd and an average of two IVs when the number of IVs is even, more than 50% valid IVs is a necessary condition. Unlike IVW, the weighted median estimator is robust to outliers which depart from the true causal line.

Another extension is the weighted mode-based estimate (MBE) [26]. Let $\hat{\beta}_i$ be the causal effect estimate in Eq. (3). The standard weights for the MBE is:

$$w_i = \text{var}(\hat{\beta}_i)^{-1} / \sum_{j=1}^n \text{var}(\hat{\beta}_j)^{-1}.$$

A simple MBE has $w_1 = w_2 = \dots = w_n = 1$. We define the

normal kernel density function as

$$f(x) = \frac{1}{b\sqrt{2\pi}} \sum_{j=1}^n w_j \exp \left[-\frac{1}{2} \left(\frac{x - \hat{\beta}_i}{b} \right)^2 \right],$$

where b is the smoothing bandwidth parameter. The MBE causal effect estimate is $\hat{\beta}_M = \max_x f(x)$. The magnitude of parameter b reflects a bias-variance trade-off. A larger b leads to a higher precision but also a larger bias. The bandwidth parameter is chosen according to the modified Silverman's bandwidth rule [27,28]. The MBE relies on the assumption named the zero modal pleiotropy assumption (ZEMPA), that is, across all IVs, the most frequent value of γ_{2i} in Eq. (2) is 0. The MBE is less biased and has lower type I error than the above mentioned methods under the null. The MBE is also less powerful in detecting causal effect than the IVW and weighted median methods, but it is more powerful than MR-Egger regression.

MR-Robust and MR-Lasso

In ordinary linear regression, one outlier can have a large impact to the regression coefficient estimate. Robust regression methods [29] have been recently applied to perform MR analysis. The current MR-Robust regression estimate by Rees *et al.* [30] is based on the MM-estimation approach by Koller and Stahel [31], which keeps asymptotic efficiency of the M-estimator and provides robustness against outliers. Lasso regression has been widely applied in high dimensional data by shrinking regression coefficients toward zero through a penalty term [32]. Recently, Lasso regression has been applied to MR analysis when individual level data is available [33,34]. Rees *et al.* [30] extended the Lasso regression to summary level data by modeling the pleiotropic effects γ_{2i} in Eq. (2). MR-Lasso considers minimizing the following objective function by including a separate intercept coefficient for each genetic variant in the MR-Egger regression but with a Lasso-penalty term:

$$\sum_{i=1}^n \text{var}(\hat{\Gamma}_i)^{-1} (\hat{\Gamma}_i - \beta_{0i} - \beta \hat{\gamma}_{0i})^2 + \lambda \sum_{i=1}^n |\beta_{0i}|. \quad (6)$$

If β_{0i} shrinks to 0 in Eq. (6), the genetic variant is considered as a valid IV. These genetic variants with a zero β_{0i} are carried forward to perform the IVW analysis to estimate the causal effect β . The MR-Lasso shares some similarity with MR-PRESSO [18], which we will introduce later. When number of invalid IVs increases, both MR-Robust and MR-Lasso have inflated false positive rate and increased the bias of a causal effect estimate.

Mixture model MRmix

With substantial differences, Qi and Chatterjee developed a parametric mixture model (MRmix) by assuming bivariate effect-size distribution of the IVs across pairs of traits [35]. MRmix is an estimating equation approach that requires the residuals, $\hat{\Gamma}_i - \beta \hat{\gamma}_i$, to follow a normal mixture model. The normal mixture model seems plausible when the genetic instruments include mediation variants, horizontal pleiotropic variants, as well as the genetic variants contributing to reverse causality. In order to achieve an unbiased causal estimate, MRmix requires the ZEMPA assumption, which is also required by MBE approach. When the sample size is large, MRmix usually shows a better trade-off between bias and variance than the approaches mentioned before, even more than when 50% IVs are invalid [35]. Similar to MR-Egger, MRmix did not performed well when the number of IVs is small.

MR-PRESSO

The MR-Lasso searches for potential outliers that may present pleiotropic effects [30]. Similarly, MR-PRESSO first identifies horizontal pleiotropic variants and then performs IVW to estimate the causal effect by removing the pleiotropic variants [18]. MR-PRESSO comprises of three steps: 1) testing whether horizontal pleiotropic variants are present through a global test; 2) performing an outlier test to detect pleiotropic variants; 3) comparing the causal estimates before and after removal of pleiotropic variants through a distortion test. The global test is based on a leave-one out approach which consists of 4 steps: 1) for each variant i , IVW regression is performed to obtain the causal effect $\hat{\beta}_{-i}$ after excluding the variant i ; 2) the residual square is calculated by $RSS_{\text{obs}}(i) = (\hat{\Gamma}_i - \hat{\beta}_{-i} \hat{\gamma}_i)^2$ and the global observed RSS is calculated by $RSS_{\text{obs}} = \sum_{i=1}^n RSS_{\text{obs}}(i)$; 3) The expected distribution of RSS under null hypothesis (no pleiotropic variants) is simulated by randomly drawing $\hat{\gamma}_i^{\text{random}}$ from a Gaussian distribution $N(\hat{\gamma}_i, \text{var}(\hat{\gamma}_i))$ and $\hat{\Gamma}_i^{\text{random}}$ from a Gaussian distribution $N(\hat{\beta}_{-i} \hat{\gamma}_i, \text{var}(\hat{\Gamma}_i))$, respectively. The expected RSS is $RSS_{\text{exp}} = \sum_{i=1}^n (RSS_{\text{exp}}(i)) = \sum_{i=1}^n (\hat{\Gamma}_i^{\text{random}} - \hat{\beta}_{-i} \hat{\gamma}_i^{\text{random}})^2$; 4) An empirical p -value is computed by taking the proportion of expected RSS greater than the observed RSS among K simulations in the third step. For the variant i , the p -value of the outlier test is calculated by taking the proportion of the expected $RSS_{\text{exp}}(i)$ greater than the observed $RSS_{\text{obs}}(i)$ among K simulations. Since MR-PRESSO estimates the causal effect after removing potential pleiotropic variants, it is less biased than IVW. However, MR-PRESSO is also

biased when the InSIDE assumption fails. In addition, MR-PRESSO is computationally intensive because a large number of simulations are necessary, especially when the number of IVs is increasing.

Iterative Mendelian randomization and pleiotropy (IMRP)

It is easy to observe that $E(\hat{\Gamma}_i) = \beta E(\hat{\gamma}_i)$ for the mediation variant G_i , and $E(\hat{\Gamma}_{1i}) = \beta E(\hat{\gamma}_{1i}) + \gamma_{2i}$ for the pleiotropic variant G'_i . Note that the effect size of a pleiotropic variant to the outcome has an additional term γ_{2i} besides the effect through the exposure. If we know the true β , we can test mediation against horizontal pleiotropy by testing the null hypothesis $\Gamma = \beta\gamma$ using a test statistic

$$T_{\text{Pleio}} = \frac{\hat{\Gamma} - \beta\hat{\gamma}}{\sqrt{\text{var}(\hat{\Gamma} - \beta\hat{\gamma})}}$$

where $\hat{\Gamma}$ and $\hat{\gamma}$ are the estimated effect sizes of a variant on E and Y , respectively. The statistic T_{pleio} asymptotically follows a standard normal distribution $N(0,1)$ when mediation is true. Under the alternative hypothesis that a variant has a pleiotropic effect, T_{pleio} departs from the mean of 0. The problem of this test is that the causal effect β is unknown. However, this problem can be solved through an iterative approach by combining the pleiotropy test and the MR analysis, which is named as iterative Mendelian randomization and pleiotropy (IMRP) [24]:

1. Performing MR-Egger analysis using all IVs to obtain the initial causal estimate of β , named as $\hat{\beta}_0$.
2. For all the IVs, performing pleiotropy test T_{pleio} by substituting β with $\hat{\beta}_{k-1}$ at the k^{th} iteration to determine which variant g_i has a horizontal pleiotropic effect at a predefined significance level α .
3. Performing IVW analysis to obtain $\hat{\beta}_k$ after removing the variants found to be significant in pleiotropy test at step 2;
4. Repeating the above steps 2 and 3 until there is no change in detected pleiotropic variants.

At step 2 above, the pleiotropy test statistic for a genetic variant is modified as

$$T_{\text{Pleio}} = \frac{\hat{\Gamma} - \beta\hat{\gamma}}{\sqrt{\text{var}(\hat{\Gamma} - \beta\hat{\gamma})}}$$

where the denominator variance is approximated by

$$\text{var}(\hat{\Gamma} - \beta\hat{\gamma}) \approx \text{var}(\hat{\Gamma}) + \beta^2 \text{var}(\hat{\gamma}) + \hat{\gamma}^2 \text{var}(\hat{\beta}) - 2\hat{\beta}\rho\sqrt{\text{var}(\hat{\Gamma})\text{var}(\hat{\gamma})}$$

where ρ is the correlation coefficient of the exposure E and the outcome Y , which can be estimated using GWAS summary statistics [15,36] or LD score regression [37]. Similarly to MR-PRESSO, the global test: $SS_{GT}^2 = \sum_{i=1}^n T_{\text{pleio},i}^2$, which approximately follows a chi-square distribution with n degrees of freedom for n independent IVs, is used to test for the presence of horizontal pleiotropic variants. A genetic variant with a T_{pleio} test p -value less than $0.05/n$, is considered as a variant having a horizontal pleiotropic effect. Thus IMRP can perform both MR analysis and test horizontal pleiotropy simultaneously.

MR analysis often assumes that the IVs are in linkage equilibrium. At a single locus, multiple variants may contribute to exposure and the outcome in different ways, as illustrated in Fig.3. Let $\hat{\Gamma}$ and $\hat{\gamma}$ vectors representing the estimated effect sizes of outcome and exposure from GWAS of M variants, respectively. Let $\hat{\Gamma} = (\hat{\Gamma}_1, \hat{\Gamma}_2, \dots, \hat{\Gamma}_M)$ and $\hat{\gamma} = (\hat{\gamma}_1, \hat{\gamma}_2, \dots, \hat{\gamma}_M)$. The test statistics T_{pleio} can be extended to M variants by $S_{\text{pleio}} = (\hat{\Gamma} - \hat{\beta}\hat{\gamma})^T \Sigma^{-1} (\hat{\Gamma} - \hat{\beta}\hat{\gamma})$, where Σ is an $M \times M$ variance-covariance matrix [24]. If working on the standardized E , Y , and genotype values, S_{pleio} can be simplified to

$$S_{\text{pleio}} = \frac{N_1 N_2}{N_1 + \hat{\beta}^2 N_2 - 2\rho\hat{\beta}\sqrt{N_1 N_2}} (\hat{\Gamma} - \hat{\beta}\hat{\gamma})^T R^{-1} (\hat{\Gamma} - \hat{\beta}\hat{\gamma})$$

where R is the linkage disequilibrium (LD) matrix among the M variants. Under the null hypothesis of mediation, S_{pleio} follows a chi-square distribution with M degrees of freedom.




Figure 3. The relationships of genetic variants, exposure and outcome. (A) Mediation: the causal variant lies on the causal path to Y . (B) Horizontal pleiotropy: the causal variant affects both E and Y . (C) Colocalization: two different causal variants at one locus affect E and Y . The red star represents the causal variant and S represents genetic markers.

A significant difference between IMRP and MR-PRESSO is that IMRP removes horizontal pleiotropic variants step by step and re-estimates the causal effect accordingly, while MR-PRESSO removes horizontal pleiotropic variants in one step. Since the causal effect estimate is sensitive to outliers, an iterative method is less biased and can advantageously detect pleiotropic variants [24]. Because usually less than 10 iterations are sufficient, iMRP is more computationally efficient than other methods, such as MR-PRESSO, MRmix, MBE, MR-Lasso or MR-Robust. iMRP shares the same computational efficiency as IVW but is almost unbiased even if half of IVs are invalid [24]. iMRP can be easily extended to include multiple variants on a locus, whether they are in LD or not, thereby testing for pleiotropy and colocalization.

APPLICATIONS

In this review, it is not our intention to list all methods and software for performing MR analysis. Rather, we introduced the basic concept and strategy for performing MR analysis. In practice, inferring causality is extremely challenging because of many unmeasured confounders, reverse causality, and weak instrument bias. Burgess *et al.* recently published guidelines for performing MR in practice [38]. Multiple analytical steps have been suggested and these steps are categorized into: motivation and scope, data sources, choice of genetic variants, variant harmonization, primary analysis, supplementary and sensitivity analyses, data presentation, and interpretation [38]. These guidelines are useful for correctly inferring causality and unbiasedly estimating the causal effect of an exposure to an outcome, given more and more practices of MR analyses have been performed in this post genome wide association era. For example, it is clearly different to infer potential causality versus to estimate the causal effect, with the former focusing on hypothesis test and the latter focusing on the size of the causal effect. In the original MR analysis by Katan [9], testing for association of a genetic variant and an outcome will be sufficient to infer the causality, as long as the genetic variant is a valid IV. Such analysis does not require genotype data for the exposure, but statistical power for testing the association between the variant and the outcome is critical. In comparison, the intervention effect of an exposure to an outcome can be estimated from MR analysis, which is usually achieved by a randomized clinical trial. In this case, it will be important to know how well the genetic variant can proxy the true causal variant, whether the genetic variant has heterogeneous effects on exposure to outcome, for example due to gene-gene interactions, and whether the associations with exposure and outcome are obtained from the same population [38,39]. Mendelian

randomization can be performed in either one sample with individual level data for both exposure and outcome or two samples with summary statistics for the exposure and the outcome in separate datasets. Although one sample with individual level data allows for flexible modeling and the exposure and outcome to be measured from the same individuals, the sample size is often small, leading to low statistical power. In comparison, two samples with summary statistics can often reach large sample sizes, but its dangers include potential different populations for the exposure and outcome, and different demographic information, which will make interpretation difficult and invalidate causal inferences [40,41]. In GWAS meta-analysis, allele flips can cause loss of statistical power when meta-analyzing multiple datasets [42,43]. The same problem can occur in a two sample MR analysis when variant harmonization is a necessary step. In general, multiple analysis methods should be performed because these methods are valid under different assumptions, which have been reviewed before. As suggested by the guidelines [38], both IVW based methods and robust methods should be applied with additional sensitivity analysis. The iMRP method [24] can assess colocalization, which will help to identify more plausible genetic IVs for MR analysis. In addition, the interpretation of findings from MR analysis should always be cautious because of multiple untestable assumptions, as is illuminated in the guidelines [38,44].

Perhaps, which genetic variants should be included in a MR analysis might be the most important decision [38]. In MR analysis, only mediation genetic variants can satisfy the three IV conditions as valid instrumental variables [45]. In fact, there is a debate about whether MR can reliably identify causality between two traits given the widespread of pleiotropy or colocalization [46,47]. The variants with pleiotropic effects violate the IV2 condition for valid IVs. Detecting horizontal pleiotropy is challenging, as demonstrated that the recent HOPS approach has an inflated type I error [48], which may reduce the power of MR analysis compared with IMRP and MR-PRESSO.

AN MR ANALYSIS OF THE CAUSALITY OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) ON CORONARY ARTERY DISEASE (CAD)

Many large-scale population studies have reported an inverse relationship between HDL-C and CAD [49,50]. A well cited MR analysis using 15 genetic variants as IVs suggested that there is no causal relationship between HDL-C and myocardial infarction [51], which was consistent with the evidence from a clinical trial study [52]. However, the MR study using more genetic variants




Figure 4. The two path diagrams for HDL-C and CAD. (A) There is no separate path through TG. (B) There is a separate path through TG.

Table 2 Causal effect estimates of HDL on CAD using 143 IVs by different MR methods

Method	Casual estimate	Standard error	95% CI	<i>p</i> -value
IVW	-0.163	0.046	(-0.252, -0.073)	3.95×10^{-4}
MR-Egger	0.06	0.084	(-0.103, 0.224)	0.47
Simple median	-0.241	0.054	(-0.348, -0.135)	8.08×10^{-4}
Weighted median	-0.062	0.046	(-0.152, 0.028)	0.174
MBE	-0.023	0.055	(-0.130, 0.084)	0.668
MRmix	-0.04	0.086	(-0.209, 0.129)	0.642
MR_PRESSO	-0.187	0.037	(-0.260, -0.115)	1.4×10^{-6}
IMRP	-0.075	0.027	(-0.128, -0.022)	5.19×10^{-3}
IMRP*	-0.062	0.031	(-0.123, -0.001)	0.043

* IMRP analysis after dropping 60 pleiotropy variants.

by Holmes *et al.* [53] suggested uncertainty in a causal role for HDL-C on CVD risk. We downloaded the GWAS summary statistics of Global Lipids Genetics Consortium (cholesterol traits) (<http://csg.sph.umich.edu/abecasis/public/lipids2013/>) and CARDIoGRAMplusC4D Consortium (coronary artery disease) (<http://www.cardiogram-plusc4d.org/data-downloads/>). We obtained 143 genome wide significant independent variants (p -value $< 5 \times 10^{-8}$) associated with HDL-C after pruning ($r^2 < 0.1$) using the software Plink [54] on a 500 kb window size. We performed the MR analysis by assuming the path diagram in Fig. 4A, representing no confounders. Table 2 presents the causal estimates and p -values for the different MR methods, including IVW, MR-Egger, median, MBE, MRmix, MR_PRESSO and IMRP. In general, IVW, simple median, and MR_PRESSO had the largest protected causal effect estimates followed by IMRP and weighted median. MRmix and MBE had the smallest protected causal estimates. Interestingly, MR-Egger had a positive causal estimate, but it was not significant. We also observed that MR-Egger and MRmix had the largest standard errors, which suggested these approaches may lose statistical power. IVW, simple median, MR_PRESSO and IMRP also suggested significant causal effect of HDL-C on CAD, but the rest of the methods did not. The IMRP analysis also identified 10 pleiotropic variants for HDL-C and CAD.

It is known that HDL-C and triglycerides (TG) are correlated. The correlation between the summary statistics of HDL-C and TC was -0.235 . It is then possible that a

genetic instrumental variable (G) has a pleiotropic effect on HDL-C and TG, therefore, conditional on HDL-C, G can still affect CAD by the mediation of TG (Fig. 4B). The mediation of TG also led to a loss of statistical power to detect pleiotropic variants for HDL-C and CAD. Thus, we performed IMRP for HDL-C and TG to identify pleiotropic variants for these two correlated traits. We were able to identify 60 pleiotropic variants among the 143 IVs. After dropping these 60 variants, the OR of HDL-C on CAD estimated by IMRP was reduced to 0.94 ($p = 0.043$), suggesting that the initial significant causal effect of HDL-C on CAD was biased because of the correlated trait TG. This example also suggests the importance to examine the traits correlated with both the exposure and outcome.

FUTURE RESEARCH

We reviewed statistical approaches for performing a Mendelian Randomization analysis using summary statistics from genome wide associations. The application of HDL-C on CAD clearly suggested that there is no uniformly best approach. There is always a trade-off between bias and efficiency. Among the methods, MR_PRESSO and IMRP are able to both perform the MR analysis and detect pleiotropic variants, and IMRP is computationally 3 order faster than MR-PRESSO and is less biased [24]. MBE and MRmix are less biased, but they also lose statistical power. Although MR is easy to conduct due to increased availability of genome data, the

challenges remain. First, one challenge is the identification of valid IVs, *i.e.*, the genetic variants have no horizontal pleiotropic between exposure and outcome. Because of the modest contribution of a genetic variant to a trait, statistical power in detecting pleiotropy can be low and requires a large sample size. New statistical approaches will be welcomed for detecting horizontal pleiotropy. Second, most of the current MR approaches assess the causal effect of one exposure on one outcome. Traits are often correlated with shared genetic contributions [55]. The correlated traits can easily lead to confounding in MR analysis, which can create multiple independent paths from a genetic IV to an outcome without pathing through the exposure, as we observed in the MR analysis of HDL-C and CAD. Multivariate MR with multiple exposures and one outcome was less developed and the current multivariate MR is unable to deal with unknown pleiotropy [56], but has advantages to solve the problems of multiple correlated exposures. Third, a single genetic variant has little prediction power. To improve the power, polygenic risk score (PRS) has been used for predicting disease and inferring putative causal relationships among traits [57]. However its false positive rate is also inflated when inferring causality [58]. A PRS has less concern caused by weak instruments. Further methodological development is necessary to unbiasedly estimate and correctly interpret the causal effect estimation through a PRS. Fourth, large GWAS also demonstrated gene-environment/life style interactions contributing to phenotype variation, and these summary statistics are available [59,60]. It will be beneficial to develop MR approaches that can be applied to summary statistics from GWAS of gene-environment interaction studies, which can potentially provide better causal effect estimations. Lastly, current large GWASs have mainly been conducted in European ancestry populations. The sample sizes in other ancestry populations are much less, resulting less identifications of genetic variants. Utilizing the GWAS information from European ancestry populations to perform MR analysis in other ancestry populations needs innovative statistical approaches. In conclusion, current genomic advances provide an unprecedented opportunity to study casual relationships among risk factors and diseases via MR analysis, and the results will lay a foundation for future, well designed randomized control trials.

ACKNOWLEDGEMENTS

This work was supported by grants HG003054 and HG011052 (to X.Z.) from the National Human Genome Research Institute (NHGRI), USA.

COMPLIANCE WITH ETHICS GUIDELINES

The author Xiaofeng Zhu declare that he has no conflict of interests.

This article is a review article and does not contain any studies with human

or animal subjects performed by the author.

REFERENCES

- Schatzkin, A., Lanza, E., Corle, D., Lance, P., Iber, F., Caan, B., Shike, M., Weissfeld, J., Burt, R., Cooper, M. R., *et al.* (2000) Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. *N. Engl. J. Med.*, 342, 1149–1155
- The Heart Outcomes Prevention Evaluation Study Investigators. (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. *N. Engl. J. Med.*, 342, 154–160
- Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N. Engl. J. Med.*, 330, 1029–1035
- Sesso, H. D., Buring, J. E., Christen, W. G., Kurth, T., Belanger, C., MacFadyen, J., Bubes, V., Manson, J. E., Glynn, R. J. and Gaziano, J. M. (2008) Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *JAMA*, 300, 2123–2133
- Davey Smith, G. and Ebrahim, S. (2001) Epidemiology—is it time to call it a day? *Int. J. Epidemiol.*, 30, 1–11
- Fewell, Z., Davey Smith, G. and Sterne, J. A. (2007) The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. *Am. J. Epidemiol.*, 166, 646–655
- Evans, D. M. and Davey Smith, G. (2015) Mendelian randomization: new applications in the coming age of hypothesis-free causality. *Annu. Rev. Genomics Hum. Genet.*, 16, 327–350
- Davey Smith, G. and Hemani, G. (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum. Mol. Genet.*, 23, R89–R98
- Katan, M. B. (1986) Apolipoprotein E isoforms, serum cholesterol, and cancer. *Lancet*, 327, 507–508
- Visscher, P. M., Wray, N. R., Zhang, Q., Sklar, P., McCarthy, M. I., Brown, M. A. and Yang, J. (2017) 10 years of GWAS discovery: biology, function, and translation. *Am. J. Hum. Genet.*, 101, 5–22
- Davey Smith, G. and Ebrahim, S. (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.*, 32, 1–22
- VanderWeele, T. J., Tchetgen Tchetgen, E. J., Cornelis, M. and Kraft, P. (2014) Methodological challenges in Mendelian randomization. *Epidemiology*, 25, 427–435
- Watanabe, K., Stringer, S., Frei, O., Umičević Mirkov, M., Polderman, T. J. C., van der Sluis, S., Andreassen, O. A., Neale, B. M. and Posthuma, D. (2018) A global view of pleiotropy and genetic architecture in complex traits. *Nat. Genet.*, 51, 1339–1134
- Solovieff, N., Cotsapas, C., Lee, P. H., Purcell, S. M. and Smoller, J. W. (2013) Pleiotropy in complex traits: challenges and strategies. *Nat. Rev. Genet.*, 14, 483–495
- Zhu, X., Feng, T., Tayo, B. O., Liang, J., Young, J. H., Franceschini, N., Smith, J. A., Yanek, L. R., Sun, Y. V., Edwards, T. L., *et al.* (2015) Meta-analysis of correlated traits via summary statistics from GWASs with an application in hypertension. *Am. J. Hum. Genet.*, 96, 21–36
- Sleiman, P. M. and Grant, S. F. (2010) Mendelian randomization in

- the era of genomewide association studies. *Clin. Chem.*, 56, 723–728
17. Angrist, J. D., Imbens, G. W. and Rubin, D. B. (1996) Identification of causal effects using instrumental variables. *J. Am. Stat. Assoc.*, 91, 444–455
 18. Verbanck, M., Chen, C. Y., Neale, B. and Do, R. (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat. Genet.*, 50, 693–698
 19. Burgess, S., Butterworth, A. and Thompson, S. G. (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet. Epidemiol.*, 37, 658–665
 20. Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N. and Thompson, J. (2017) A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat. Med.*, 36, 1783–1802
 21. Borenstein, M., Hedges, L., Higgins, J. and Rothstein, H. (2009) Generality of the basic inverse-variance method. In: *Introduction to Meta-analysis*. Wiley
 22. Bowden, J., Davey Smith, G. and Burgess, S. (2015) Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.*, 44, 512–525
 23. Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ*, 315, 629–634
 24. Zhu, X., Li, X., Xu, R., Wang, T. (2020) An iterative approach to detect pleiotropy and perform Mendelian randomization analysis using GWAS summary statistics. Under review
 25. Bowden, J., Davey Smith, G., Haycock, P. C. and Burgess, S. (2016) Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet. Epidemiol.*, 40, 304–314
 26. Hartwig, F. P., Davey Smith, G. and Bowden, J. (2017) Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int. J. Epidemiol.*, 46, 1985–1998
 27. Bickel, D. R. (2003) Robust and efficient estimation of the mode of continuous data: the mode as a viable measure of central tendency. *J. Stat. Comput. Simul.*, 73, 899–912
 28. Bickel, D. R. and Fruhwirth, R. (2006) On a fast, robust estimator of the mode: Comparisons to other robust estimators with applications. *Comput. Stat. Data Anal.*, 50, 3500–3530
 29. Huber, P. J. and Ronchetti, E. (2009) *Robust Statistics*, 2nd edition, Hoboken, N.J. (ed.) Wiley
 30. Rees, J. M. B., Wood, A. M., Dudbridge, F. and Burgess, S. (2019) Robust methods in Mendelian randomization via penalization of heterogeneous causal estimates. *PLoS One*, 14, e0222362
 31. Koller, M. and Stahel, W. A. (2011) Sharpening Wald-type inference in robust regression for small samples. *Comput. Stat. Data Anal.*, 55, 2504–2515
 32. Tibshirani, R. (1996) Regression shrinkage and selection via the Lasso. *J. R. Stat. Soc. B*, 58, 267–288
 33. Kang, H., Zhang, A. R., Cai, T. T. and Small, D. S. (2016) Instrumental variables estimation with some invalid instruments and its application to Mendelian randomization. *J. Am. Stat. Assoc.*, 111, 132–144
 34. Windmeijer, F., Farbmacher, H., Davies, N. and Davey Smith, G. (2019) On the use of the Lasso for instrumental variables estimation with some invalid instruments. *J. Am. Stat. Assoc.*, 114, 1339–1350
 35. Qi, G. and Chatterjee, N. (2019) Mendelian randomization analysis using mixture models for robust and efficient estimation of causal effects. *Nat. Commun.*, 10, 1941
 36. Park, H., Li, X., Song, Y. E., He, K. Y. and Zhu, X. (2016) Multivariate analysis of anthropometric traits using summary statistics of genome-wide association studies from GIANT consortium. *PLoS One*, 11, e0163912
 37. Bulik-Sullivan, B. K., Loh, P. R., Finucane, H. K., Ripke, S., Yang, J., the Schizophrenia Working Group of the Psychiatric Genomics Consortium, Patterson, N., Daly, M. J., Price, A. L. and Neale, B. M. (2015) LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.*, 47, 291–295
 38. Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., *et al.* (2019) Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res.*, 4, 186
 39. Hernán, M. A. and Robins, J. M. (2006) Instruments for causal inference: an epidemiologist’s dream? *Epidemiology*, 17, 360–372
 40. Labrecque, J. A. and Swanson, S. A. (2019) Interpretation and potential biases of Mendelian randomization estimates with time-varying exposures. *Am. J. Epidemiol.*, 188, 231–238
 41. Swanson, S. A., Labrecque, J. and Hernán, M. A. (2018) Causal null hypotheses of sustained treatment strategies: What can be tested with an instrumental variable? *Eur. J. Epidemiol.*, 33, 723–728
 42. Franceschini, N., Fox, E., Zhang, Z., Edwards, T. L., Nalls, M. A., Sung, Y. J., Tayo, B. O., Sun, Y. V., Gottesman, O., Adeyemo, A., *et al.* (2013) Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations. *Am. J. Hum. Genet.*, 93, 545–554
 43. Liang, J., Le, T. H., Edwards, D. R. V., Tayo, B. O., Gaulton, K. J., Smith, J. A., Lu, Y., Jensen, R. A., Chen, G., Yanek, L. R., *et al.* (2017) Single-trait and multi-trait genome-wide association analyses identify novel loci for blood pressure in African-ancestry populations. *PLoS Genet.*, 13, e1006728
 44. Smith, G. D., Davies, N. M., Dimou, N., Egger, M., Gallo, V., Golub, R., Higgins, J. P. T., Langenberg, C., Loder, E. W., Richards, J. B., *et al.* (2020) STROBE-MR: Guidelines for strengthening the reporting of Mendelian randomization studies. *PeerJ Preprints* 7, e27857v1
 45. Burgess, S., Bowden, J., Fall, T., Ingelsson, E. and Thompson, S. G. (2017) Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. *Epidemiology*, 28, 30–42
 46. Pickrell, J. (2015) Fulfilling the promise of Mendelian randomization. *bioRxiv*, 018150
 47. Davey Smith, G. (2015) Mendelian randomization: a premature burial? *bioRxiv*, 021386

48. Jordan, D. M., Verbanck, M. and Do, R. (2019) HOPS: a quantitative score reveals pervasive horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of human traits and diseases. *Genome Biol.*, 20, 222
49. The Emerging Risk Factors Collaboration (2009) Major lipids, apolipoproteins, and risk of vascular disease. *JAMA*, 302, 1993–2000
50. Lewington, S., Whitlock, G., Clarke, R., Sherliker, P., Emberson, J., Halsey, J., Qizilbash, N., Peto, R., Collins, R., Collins, R., *et al.* (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet*, 370, 1829–1839
51. Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., *et al.* (2012) Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. *Lancet*, 380, 572–580
52. Geller, A. S., Polisecki, E. Y., Diffenderfer, M. R., Asztalos, B. F., Karathanasis, S. K., Hegele, R. A. and Schaefer, E. J. (2018) Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. *J. Lipid Res.*, 59, 2421–2435
53. Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., *et al.* (2015) Mendelian randomization of blood lipids for coronary heart disease. *Eur. Heart J.*, 36, 539–550
54. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A., Bender, D., Maller, J., Sklar, P., de Bakker, P. I., Daly, M. J., *et al.* (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.*, 81, 559–575
55. Cortes, A., Albers, P. K., Dendrou, C. A., Fugger, L. and McVean, G. (2020) Identifying cross-disease components of genetic risk across hospital data in the UK Biobank. *Nat. Genet.*, 52, 126–134
56. Burgess, S. and Thompson, S. G. (2015) Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am. J. Epidemiol.*, 181, 251–260
57. Davies, R. B. (1980) The distribution of a linear combination of χ^2 random variables. *J. R. Stat. Soc. C Appl. Stat.*, 29, 323–333
58. Richardson, T. G., Harrison, S., Hemani, G. and Davey Smith, G. (2019) An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome. *eLife*, 8, e43657
59. Bentley, A. R., Sung, Y. J., Brown, M. R., Winkler, T. W., Kraja, A. T., Ntalla, I., Schwander, K., Chasman, D. I., Lim, E., Deng, X., *et al.* (2019) Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. *Nat. Genet.*, 51, 636–648
60. Sung, Y. J., Winkler, T. W., de Las Fuentes, L., Bentley, A. R., Brown, M. R., Kraja, A. T., Schwander, K., Ntalla, I., Guo, X., Franceschini, N., *et al.* (2018) A Large-scale multi-ancestry genome-wide study accounting for smoking behavior identifies multiple significant loci for blood pressure. *Am. J. Hum. Genet.*, 102, 375–400